Business Description
Arbutus Biopharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA03879J1003
Description
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 71.27 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -5.31 | |||||
| Beneish M-Score | -1.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.2 | |||||
| 3-Year EBITDA Growth Rate | 17.5 | |||||
| 3-Year EPS without NRI Growth Rate | 23.7 | |||||
| 3-Year FCF Growth Rate | 8.4 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.76 | |||||
| 9-Day RSI | 43.18 | |||||
| 14-Day RSI | 47.04 | |||||
| 6-1 Month Momentum % | 36.97 | |||||
| 12-1 Month Momentum % | 0.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.87 | |||||
| Quick Ratio | 5.87 | |||||
| Cash Ratio | 5.6 | |||||
| Days Sales Outstanding | 42.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.2 | |||||
| Shareholder Yield % | -5.99 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -430.15 | |||||
| Net Margin % | -401.57 | |||||
| FCF Margin % | -478.65 | |||||
| ROE % | -56.84 | |||||
| ROA % | -42.04 | |||||
| ROIC % | -192.33 | |||||
| ROC (Joel Greenblatt) % | -1099.75 | |||||
| ROCE % | -48.97 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 24.82 | |||||
| PB Ratio | 4.38 | |||||
| Price-to-Tangible-Book | 4.38 | |||||
| EV-to-EBIT | -5.08 | |||||
| EV-to-EBITDA | -5.18 | |||||
| EV-to-Revenue | 20.27 | |||||
| EV-to-Forward-Revenue | 39.66 | |||||
| EV-to-FCF | -4.23 | |||||
| Price-to-Median-PS-Value | 1.2 | |||||
| Price-to-Net-Current-Asset-Value | 4.97 | |||||
| Price-to-Net-Cash | 5.25 | |||||
| Earnings Yield (Greenblatt) % | -19.69 | |||||
| FCF Yield % | -17.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arbutus Biopharma Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 16.871 | ||
| EPS (TTM) (€) | -0.407 | ||
| Beta | 0.92 | ||
| Volatility % | 43.73 | ||
| 14-Day RSI | 47.04 | ||
| 14-Day ATR (€) | 0.077032 | ||
| 20-Day SMA (€) | 2.60345 | ||
| 12-1 Month Momentum % | 0.89 | ||
| 52-Week Range (€) | 1.534 - 3 | ||
| Shares Outstanding (Mil) | 180.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arbutus Biopharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arbutus Biopharma Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arbutus Biopharma Corp Frequently Asked Questions
What is Arbutus Biopharma Corp(STU:I9DN)'s stock price today?
The current price of STU:I9DN is €2.50. The 52 week high of STU:I9DN is €3.00 and 52 week low is €1.53.
When is next earnings date of Arbutus Biopharma Corp(STU:I9DN)?
The next earnings date of Arbutus Biopharma Corp(STU:I9DN) is 2024-05-02.
Does Arbutus Biopharma Corp(STU:I9DN) pay dividends? If so, how much?
Arbutus Biopharma Corp(STU:I9DN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers